Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M

Amylyx Pharmaceuticals, Inc.

Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.
Total purchase price $35.1M plus determined cure costs capped at $277,703.63.
Transaction subject to Bankruptcy Court approval; Eiger filed Chapter 11 on April 1, 2024.
Deal includes assigned contracts and regulatory filings; closing expected after court order.
Amylyx deposits $1.755M into escrow as deposit per approved bid procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.